NEOS Investment Management LLC Increases Stake in Guardant Health, Inc. (NASDAQ:GH)

NEOS Investment Management LLC increased its holdings in Guardant Health, Inc. (NASDAQ:GH) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 36,120 shares of the company’s stock after purchasing an additional 3,553 shares during the quarter. NEOS Investment Management LLC’s holdings in Guardant Health were worth $1,103,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in GH. Lord Abbett & CO. LLC bought a new position in shares of Guardant Health in the third quarter worth approximately $15,624,000. Guyasuta Investment Advisors Inc. purchased a new stake in Guardant Health during the 4th quarter valued at $206,000. Geode Capital Management LLC grew its holdings in Guardant Health by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock worth $64,754,000 after acquiring an additional 29,686 shares during the last quarter. Entropy Technologies LP purchased a new position in shares of Guardant Health in the fourth quarter valued at about $377,000. Finally, Pier Capital LLC increased its position in shares of Guardant Health by 36.7% in the third quarter. Pier Capital LLC now owns 158,429 shares of the company’s stock valued at $3,634,000 after acquiring an additional 42,575 shares during the period. 92.60% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on GH. Scotiabank raised their target price on Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 24th. Guggenheim reiterated a “buy” rating and issued a $56.00 price objective on shares of Guardant Health in a research report on Monday, February 24th. Piper Sandler upped their target price on Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Stifel Nicolaus lifted their price target on shares of Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Twenty equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $48.95.

Guardant Health Stock Down 4.5 %

GH stock opened at $43.14 on Friday. The business has a 50 day moving average of $44.66 and a 200 day moving average of $34.30. The firm has a market cap of $5.32 billion, a PE ratio of -12.12 and a beta of 1.50. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $50.89.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The company had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. On average, research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.